OptimizeRx Corporation reaffirmed financial guidance for the year 2022. The company is reaffirming its full year financial outlook for 2022 and continues to expect net revenues of $80 million to $85 million, representing year-over-year growth of 31% to 39%, respectively.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.94 USD | +5.20% | -1.07% | -9.57% |
14/05 | Transcript : OptimizeRx Corporation, Q1 2024 Earnings Call, May 14, 2024 | |
14/05 | OptimizeRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.57% | 236M | |
+29.97% | 448B | |
+32.84% | 279B | |
+4.37% | 134B | |
+29.26% | 93.43B | |
+6.12% | 91.72B | |
+63.99% | 61.12B | |
+14.10% | 46.14B | |
+25.07% | 37.49B | |
-1.67% | 35.1B |
- Stock Market
- Equities
- OPRX Stock
- News OptimizeRx Corporation
- OptimizeRx Corporation Reaffirms Financial Guidance for the Year 2022